- Home
- JANX vs SHO Comparison
JANX vs SHO Comparison
Compare JANX & SHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- SHO
- Stock Information
- Founded
- JANX 2017
- SHO 1995
- Country
- JANX United States
- SHO United States
- Employees
- JANX N/A
- SHO N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- SHO Hotels/Resorts
- Sector
- JANX Health Care
- SHO Consumer Discretionary
- Exchange
- JANX Nasdaq
- SHO Nasdaq
- Market Cap
- JANX 1.5B
- SHO 1.7B
- IPO Year
- JANX 2021
- SHO 1995
- Fundamental
- Price
- JANX $25.96
- SHO $9.02
- Analyst Decision
- JANX Strong Buy
- SHO Hold
- Analyst Count
- JANX 8
- SHO 7
- Target Price
- JANX $90.63
- SHO $9.21
- AVG Volume (30 Days)
- JANX 839.1K
- SHO 1.9M
- Earning Date
- JANX 08-06-2025
- SHO 08-06-2025
- Dividend Yield
- JANX N/A
- SHO 3.97%
- EPS Growth
- JANX N/A
- SHO N/A
- EPS
- JANX N/A
- SHO 0.10
- Revenue
- JANX $9,336,000.00
- SHO $922,708,000.00
- Revenue This Year
- JANX N/A
- SHO $7.51
- Revenue Next Year
- JANX $1,470.82
- SHO $3.51
- P/E Ratio
- JANX N/A
- SHO $92.51
- Revenue Growth
- JANX 28.12
- SHO N/A
- 52 Week Low
- JANX $22.48
- SHO $7.45
- 52 Week High
- JANX $71.71
- SHO $12.41
- Technical
- Relative Strength Index (RSI)
- JANX 53.36
- SHO 54.02
- Support Level
- JANX $25.81
- SHO $8.90
- Resistance Level
- JANX $27.31
- SHO $9.18
- Average True Range (ATR)
- JANX 1.30
- SHO 0.20
- MACD
- JANX 0.08
- SHO -0.00
- Stochastic Oscillator
- JANX 45.02
- SHO 50.00
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.